Deferasirox is a selective oral iron chelator that binds ferric iron with high affinity, used for chronic iron overload due to blood transfusions in conditions such as thalassaemia and sickle cell disease. Simson Pharma's Deferasirox reference standard and impurities support stability-indicating testing for this important iron-chelation therapy.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Deferasirox Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.